Enhancing anti-gastrointestinal cancer activities of CLDN18.2 CAR-T armored with novel synthetic NKG2D receptors Containing DAP10 and DAP12 signaling domains.
M. Sun, H. Wang, R. Hao…·Y. Cheng
This paper develops a CAR-T therapy for gastrointestinal cancers by combining CLDN18.2 targeting with synthetic NKG2D receptors containing DAP10 and DAP12 domains, improving efficacy against heterogeneous tumors.